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Converging lines of clinical and epidemiological evidence suggest that viral infections in early developmental stages may be a
causal factor in neuropsychiatric disorders such as schizophrenia, bipolar disorder, and autism-spectrum disorders. This etiological
link, however, remains controversial in view of the lack of consistent and reproducible associations between viruses and mental
illness. Animal models of virus-induced neurobehavioral disturbances afford powerful tools to test etiological hypotheses and
explore pathophysiological mechanisms. Prenatal or neonatal inoculations of neurotropic agents (such as herpes-, influenza-, and
retroviruses) in rodents result in a broad spectrum of long-term alterations reminiscent of psychiatric abnormalities. Nevertheless,
the complexity of these sequelae often poses methodological and interpretational challenges and thwarts their characterization.
The recent conceptual advancements in psychiatric nosology and behavioral science may help determine new heuristic criteria
to enhance the translational value of these models. A particularly critical issue is the identification of intermediate phenotypes,
defined as quantifiable factors representing single neurochemical, neuropsychological, or neuroanatomical aspects of a diagnostic
category. In this paper, we examine how the employment of these novel concepts may lead to new methodological refinements in
the study of virus-induced neurobehavioral sequelae through animal models.
1. The Role of Viruses in Psychiatric Disorders
The implication of viruses in the pathogenesis of neuropsy-
chiatric disorders has been posited since the foundations
of modern psychiatry. Few years after the outbreak of
the 1918 flu pandemic, the nosographic analogies between
postinfluenza encephalitic manifestations and psychotic
traits prompted Menninger [1] to conjecture an infective
etiology for some subtypes of schizophrenia. Although
this hypothesis sank into relative obsolescence during the
following decades, the identification of lentiviruses rekindled
enthusiasm for the viral theory of mental disorders and
laid the foundations of psychovirology as a novel discipline
[2]. Over the last 25 years, numerous studies have shown
that viral infections of the central nervous system are
potentially conducive to profound behavioral and cognitive
perturbations. Typical outcomes of viral encephalitis, for
instance, encompass impairments in sensory reactivity and
information processing, emotional lability, and sleep distur-
bances. Notably, the severity of some postencephalitic mani-
festations is often correlated to the degree of morphological
and functional damage induced by both the viral infection
and/or the ensuing immune response [3]. A detailed analysis
of these phenomena is beyond the scope of this paper and
can be found elsewhere [4, 5].
Neuropsychiatric sequelae of overt infectious processes,
while accounting for few documented cases of mental illness,
offer a compelling theoretical platform to postulate the
role of viruses in the pathophysiology of schizophrenia
and other neurodevelopmental syndromes. According to
the prevalent theories, the pathogenesis of these disorders
may be initiated or contributed by early exposure to low-
virulence, neurotropic viruses. The resulting infection, albeit
subclinical, may interfere with key neurogenetic processes
and lead to insidious, potentially ingravescent functional
impairments. Specifically, this neuropathic process has been
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shown to reflect the combination of the insults mediated by
the cytopathic and mutagenic effects of the virus [6], as well
as the immune response [7–10]. Furthermore, the chronic
enactment of compensatory, neuroprotective responses may
also contribute to the pathogenesis of these disorders. For
example, certain clusters of psychotic manifestations may
result from the outcome of the hippocampal dysregulation by
virus-mediated and endogenous anticonvulsant mechanisms
[11]. The confluence of these processes with neurodevel-
opmental mechanisms and other factors of vulnerability
(both genetic and environmental) may result in severe
neurochemical imbalances, brain architectural irregularities,
and mental derangement.
The implication of viruses in mental disorders is sup-
ported by several lines of epidemiological evidence. Prenatal
or perinatal viral infections are risk factors for schizophrenia
and autism-spectrum disorders [12, 13]. Numerous epi-
demiological surveys have also documented a birth excess of
schizophrenia and bipolar patients in winter and spring [14–
17] or seasonal correlations between incidence of autism-
spectrum disorders and viral outbreaks [18–22].
The viral hypothesis of mental disorders is also corrobo-
rated by clinical evidence. Several investigations have shown
the presence of viral antigens and antibodies in plasma or
post-mortem samples of mental patients [23–25]. In partic-
ular, these studies have revealed that schizophrenia may be
associated with several families of viruses, including herpes
viruses [26–30], orthomyxoviruses [31–35], and retroviruses
[36, 37]. It is worth noting that most of these agents have also
been associated with autism-spectrum disorders [38, 39],
bipolar disorder [40–42], and other psychiatric conditions
[43].
However, there remain numerous inconsistencies across
different clinical studies concerning the role of viruses in
psychiatric disorders. The lack of reproducible associations
may be contingent on different parameters related to the
virus (rarity, reproductive cycle, virulence, latency), host
(age at the time of infection, genetic vulnerability, immune
responsiveness) and infective process (modality of trans-
mission, duration and severity of the infection, patterns
of viral replication and distribution within the host, viral
interaction with other infective agents and environmental
factors). Other discrepancies may reflect methodological
limitations in the design and execution of the studies,
including imprecise diagnostic assessments, poor sensitivity
and specificity of survey criteria, insufficient number of
subjects, low statistical power, and lack of adequate controls.
2. Animal Models of Virus-Induced
Neurobehavioral Sequelae
2.1. Choice of Animal. Animal models provide a powerful
tool to explore the biological substrates of virus-induced
neuropsychiatric sequelae in a controlled experimental set-
ting. The best target to address specific pathophysiological
hypotheses is afforded by mammalian species, and in
particular nonhuman primates, in view of their relatively
high degree of anatomical and phylogenetic continuity
with humans. Ethical considerations, however, dictate that
experimentation on monkeys should be strictly limited to
exceptional circumstances, where no viable alternatives are
available, such as the research on simian immunodeficiency
virus as a neuroAIDS model. Rodents offer an attractive
compromise for research on viral neurobehavioral disorders,
by virtue of their advantageous characteristics, including
small size, short reproductive cycle, and cost-effectiveness.
The inherent differences between humans and rodent
species in the key factors of pathogenesis of virus-induced
sequelae—such as neurodevelopmental mechanisms and
immune reactivity—are an important limiting factor in the
application of these models. These shortcomings notwith-
standing, rodent models have a high level of validity, which
is warranted by common physiological, neurobiological, and
ethological characteristics. Indeed, investigations on mice
(Mus musculus) and rats (Rattus norvegicus) have become
the richest source of knowledge on the neural substrates
and molecular underpinnings of post-infectious behavioral
dysregulations. These models have been instrumental to the
acquisition of a large body of information on virus-induced
neurobehavioral alterations.
A thorough overview of the body of evidence on the
specific virus-induced neurobehavioral alterations is covered
in the excellent reviews by Tomonaga [5] and Weed and
Gold [44]. In the following sections, we will focus on the
key conceptual issues and advances in rodent models of
virus-induced neurobehavioral disorders and indicate new
potential experimental directions to reduce confounding
factors in the analysis of these abnormalities.
2.2. Validity. Rodent models of virus-induced neurobe-
havioral alterations are a striking example of homologous
models, aimed at reproducing the etiology, pathophysiology
and symptomatic presentation of psychiatric disorders. In
substantial agreement with the classical criteria of validity
for animal models [45], the degree of isomorphism between
virus-induced sequelae and the corresponding psychiatric
should be assessed at the following four levels:
(i) etiological validity, based on the epidemiological
and/or clinical relevance of the pathogen agents to the
targeted disorder;
(ii) face validity, describing the analogies between the
virus-induced behavioral manifestations of the ani-
mal model and the signs and symptoms of the
targeted psychiatric disorder;
(iii) predictive validity, signifying the responsiveness of
the model to clinically efficacious treatments (such as
antipsychotic agents for schizophrenia etc.);
(iv) construct validity, representing the pathophysiologi-
cal congruence between animal and human neurobi-
ological alterations.
A prominent case of fulfillment of the above standards is
illustrated by the outcomes of prenatal and/or early postnatal
exposure to influenza virus as a model of schizophrenia:
(i) the etiological validity of the model is strongly
supported by the aforementioned epidemiological
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association between influenza and psychotic disor-
ders;
(ii) the face validity of the model is ensured by the
resemblance between the symptoms of schizophrenia
and the array of behavioral changes observed in the
animals, including alterations in exploratory activity,
social behavior, emotional reactivity, gating, sleep
patterns, working, and spatial memory [46–51];
(iii) the predictive validity of the model is based on its
responsiveness to atypical antipsychotic agents [50];
(iv) the construct validity of the model is warranted by
the implication of some of the key areas in the
pathophysiology of schizophrenia, such as neocor-
tex and hippocampus [52, 53], as well as by the
demonstration of alterations in line with those shown
in these disorders, such as alterations of pyramidal
neurons, glia, and myelination processes [52–59].
Another example is represented by rodents subjected
to early HSV inoculation, which exhibit an array of
schizophrenia-related deficits, including preattentional and
cognitive impairments [60–63] and alterations of the sero-
tonergic system and hippocampus [64, 65].
Although the adoption of stringent validity criteria
ensures high sensitivity and specificity of preclinical findings,
caution should be exercised in their utilization. In partic-
ular, over-reliance on the use of reference compounds as
gold standards for predictive validity—such as conventional
antipsychotic agents for models of virus-induced psychotic
disorders—has been shown to impoverish the translational
potential of numerous models [66, 67]. Furthermore, the
etiological validity of these models is inherently tempered
by the impossibility to reproduce specific virus-host inter-
actions. In view of these considerations, several lines of
research have recently focused on the identification of
relevant behavioral manifestations and pathophysiological
alterations induced by neurotropic viruses, irrespective of
their proven implication of human pathology. This con-
cept is clearly exemplified by experimentation on borna-
disease virus (BDV), a single-stranded RNA virus whose
association with in behavioral disorders is well-established
in animals, yet still highly controversial in humans [68, 69].
BDV infection triggers a broad spectrum of abnormali-
ties in animals, which encompass emotional impairments,
aggressiveness, stereotyped behavior, and cognitive deficits
[70, 71]. These alterations are supported by neurochemical
changes in dopamine and neurotrophin signaling [71–76].
These and other studies of viral effects on neurotransmitter,
neurohormonal, neurotrophic systems, and inflammatory
mediators have represented a useful template to study the
mechanisms of virus- and immune-mediated behavioral
disorders, generalizable to other viral and pathogen agents.
2.3. Intermediate Phenotypes and Endophenotypes. A critical
complication posed by models of psychiatric disorders is
based on the absence of biomarkers and other quantitative
indices in the current criteria of classification outlined in
the Diagnostic and Statistical Manual of Mental Disorders
(DMS) IV TR. This absence results in a mismatch between
the diagnostic and the pathophysiological perspectives.
Nosologic categories such as schizophrenia, for example,
are merely based on limited symptomatic and diagnostic
criteria and may be broad rubrics encompassing a number
of heterogeneous disorders with overlapping semeiological
features. Conversely, conditions with similar etiology and
pathophysiology may be set apart by artificial diagnostic
criteria. In this perspective, viral sequelae may only represent
specific subsets of mental disorders.
The acknowledgement of this scenario has fostered a
lively academic debate on the reorganization of translational
principles in psychiatry and reiterated the necessity of
incorporating pathophysiological criteria in the classification
of mental disorders [67]. This discussion has led to the
implementation of quantitative, pathophysiological, and
dimensional criteria in the new conceptual guidelines for the
next edition of the DSM (DSM-V) [77–79].
An important corollary of this theoretical reorganiza-
tion of translational science has been the development of
the concept of intermediate phenotypes. These quantifiable
factors represent neuroanatomical, biochemical, neurophys-
iological, neuropsychological, or cognitive traits, reflecting a
simpler architecture than the whole array of abnormalities
featured in a diagnostic category [80]. An important variant
of this notion is that of endophenotype, defined as a heritable
intermediate phenotype which, albeit not inherently patho-
logical, is an element of vulnerability to mental disorders
[81, 82]. The validation of a biological characteristic as an
endophenotype is dictated by a set of criteria that reflect and
emphasize its genetic nature, including cosegregation in non-
affected relatives of the probands [83, 84].
A typical example of a well-established neuropsycho-
logical endophenotype is the prepulse inhibition (PPI) of
the startle reflex. PPI is the reduction in startle response
elicited by a strong sensory stimulus that occurs when the
latter is preceded by a weaker signal [85]. This parameter is
considered a highly dependable index for the measurement
of gating function, and its deficits are typically observed in
schizophrenia, bipolar disorder, autism, and other disorders
[86]. Notably, PPI deficits are not only featured by mental
patients, but also by their nonaffected relatives [87, 88].
Although the manifestations of endophenotypes may
become apparent only in correspondence of specific envi-
ronmental contingencies, they are always active and inde-
pendent from the symptomatic fluctuations of the associated
disorder. Furthermore, endophenotypes are generally not
pathognomonic of specific mental disorders, but they are
often featured in different diagnostic categories, probably
signifying common pathophysiological mechanisms between
disorders.
Endophenotypes have recently garnered increasing pop-
ularity in psychiatry, as they offer a suitable operational
appendix to the body of knowledge derived from the charac-
terization of human genome and generation of multiple lines
of transgenic rodents. Furthermore, this strategy may be vital
for the progress in our understanding of neurodevelopmen-
tal disorders [89–93]. The dissection of complex behavioral
syndromes into more elementary “building blocks”—such as
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quantifiable responses related to specific neuropsychological
traits—is more amenable to effective translational strategies
and may lead to a profitable exchange of information
between human and animal studies and the identification
of common indices in mental patients and animal models
[67, 94, 95].
Analogous considerations can be applied to the case of
virus-derived neurobehavioral abnormalities. In particular,
the identification of intermediate phenotypes in virus-
based animal models is critical to simplify the mapping
of their abnormalities, elucidate pathophysiological links,
and enhance the translational value of these experimental
preparations. In parallel with the criteria postulated for the
definition of endophenotypes in behavioral genetics, virus-
dependent intermediate phenotypes could be theorized as
outcomes of viral (or immune) action on specific neuro-
biological substrates. These neurochemical, morphological,
or psychological traits should reflect specific factors of
vulnerability to a neurodevelopmental disorder, but not
overt pathological manifestations. Accordingly, they should
also be observed in mental patients as well as in non-
affected individuals with an overlapping history of early viral
infection (or at least analogous antibody panels, signifying
similar antigenic history).
The identification of these targets in humans, however, is
extremely arduous, in view of the high variability of natural
conditions affecting the infectious process and its outcomes.
Thus, high-quality characterization of animal models is
indispensable to delineate future strategies on clinical targets.
To this end, the design of behavioral studies should place
particular emphasis on quantitative, dimensional, and time-
specific relations between face and construct validity. For
instance, experiments on viral sequelae should take into
account the behavioral and cognitive properties associated
with the brain areas of viral tropism. Furthermore, the
analysis of virus-induced disorders should be performed
across different time points, to capture the progressive
changes induced by the ongoing virus-mediated insult
(through neurotoxic proteins and oxidative stress), immune
responses (through cytokine release, microglial activation,
etc.), neurodevelopmental processes, and neural compen-
satory mechanisms. For example, this conceptual framework
has been employed to study the time-related effects of
maternal influenza on cortical, hippocampal, and cerebellar
morphogenesis [53, 96].
2.4. Experimental Design and Analysis: Tackling Problems of
Inconsistency and Reproducibility. The experimental design
related to the phenotyping of virus-induced sequelae is
based on an extremely complex algorithm, which reflects a
top-down progression from generic, multimodal paradigms
towards increasingly specific tasks for the measurement of
subtle traits. This approach is instrumental for the decon-
structing strategy used for the identification of intermediate
phenotypes.
As previously mentioned, the evolving state of the
disorder dictates the need for a meticulous temporal doc-
umentation of the course of viral pathogenesis, which
should be accomplished through periodic examinations
of the infected rodents during their major developmental
milestones. A general protocol for the assessment of neurobe-
havioral sequelae of experimental infections is outlined in
Table 1. The phenotypic assessment should typically include
auxological (size, body weight, etc.), physiological (heart
rate, breathing frequency, body temperature, and food and
water intake), and neurological parameters (posture, gait,
motor coordination, reflex integrity, sensory perception, and
pain sensitivity) [97]. Impairments in these functions may
call for specific adjustments of the experimental design and
testing procedure. For example, acoustic alterations may
require paradigms relying on alternative sensory modalities,
such as visual or tactile. Similarly, deficits in locomotor
and cardiorespiratory functions may justify the selection of
smaller arenas for behavioral testing and shorter experimen-
tal duration (to avoid fatigue). Finally, observations should
include a brief ethological analysis of nesting, grooming,
exploratory, and social behaviors, and so forth. This pre-
liminary monitoring can be critical to refine hypotheses on
potential behavioral impairments to test in the experimental
phase.
The identification of intermediate behavioral phenotypes
induced by early viral infection should be performed with a
battery of subsequent tests. The operational procedure starts
with the recognition of behavioral differences between virus-
infected rodents and their controls in highly standardized
paradigms, such as the open field. Alterations of the
performance in this apparatus can inform on numerous
components of behavioral and cognitive repertoire, such as
locomotion, exploration, spontaneous activity, anxiety-like
responses, behavioral rigidity, and memory (upon repeated
exposure to the apparatus) [98]. The spectrum of open-
field behaviors directs the selection of new paradigms to
further qualify the nature of the observed variations. Sub-
sequent adjustments towards progressively narrower targets
reshape the architecture of the decisional flowchart and
allow the detection of specific intermediate phenotypes.
Testing conditions should always be optimized in view
of the specific aspects of the experimentation, to capture
potential variations with the highest sensitivity. In this
context, environmental variations (such as light and noise
level) in the experimental setting, as well as the employment
of pharmacological agents can be extremely valuable to
reveal hidden non-apparent traits and elucidate underlying
neurobiological mechanisms.
As no single assay can completely model a psychiatric
phenotype, conclusions based on a limited set of paradigms
can prove detrimental to the analysis and lead to false positive
(or negative) results. Instead, characterization of phenotypes
should be based on a multimodal approach with com-
plementary paradigms that can capture different facets of
behavioral domains. More generally, experimental strategies
aimed at the identification of virus-induced intermediate
phenotypes should always be multifactorial and employ
several complementary measures (including non-behavioral
indices, such as neurochemical, electrophysiological, and
physiological parameters). The documentation of coherent
indications from multiple variables ensures the translational
quality and the construct validity of the findings.
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Table 1: Experimental protocol for phenotyping of neurobehavioral sequelae of experimental infections in rodents.
Preliminary physical assessment:
Auxological parameters (body size, weight, growth rate, dentition, and sexual development)
Physiological parameters (heart rate, breathing frequency, rectal temperature, food and water daily intake, and menstrual cycle)
Presence of pathological features (non-experimental infections, fur loss, ringtail, chromodacryorrhea, adynamic ileus, neoplasms, etc.)
Neurological assessment:
Sensory acuity and discrimination (vision, hearing, olfaction, taste, vibrissae activity and somatosensation, and pain sensitivity)
Motor assessment (posture, orienting, prehension, gait, motor coordination, reflex integrity, Arousal and sleep patterns)
Ethological assessment of spontaneous behavior:
Home-cage behavior (locomotion, nesting, etc.)
Exploratory activity (novelty responsiveness and foraging behavior)
Social behavior (playing behavior, aggressive and defensive responses, mating, maternal behavior)
Grooming behavior (syntactical and nonchain)
Age-specific behaviors (suckling and huddling in pups, food reaching and social play in adolescent rodents, etc.)
Presence of abnormal behaviors (stereotyped behaviors and maladaptive reactivity to stimuli, etc.)
Standardized behavioral assays:
Multimodal assays (open field, object exploration, etc.)
Domain-specific assays
One of the most vexing and insidious aspects of
behavioral research on virus-induced sequelae is the low
reproducibility of findings across different laboratories and
settings. This problem is generally ascribed to a large
contingent of numerous unpredictable and irreducible envi-
ronmental variables that cannot be fully accounted for
in behavioral testing. Low reproducibility undermines the
progress of behavioral neuroscience and the improvement
of translational strategies, calling for urgent strategies to
counter this problem.
One of the key strategies to maximize reproducibility in
behavioral research is the standardization of experimental
procedures. Nevertheless, this approach has been recently
challenged [99], in light of the discrepant findings yielded by
behavioral experiments performed with identical protocols
in different laboratories. These authors have suggested an
alternative approach to reduce intergroup variance, consist-
ing in the heterogenization of experimental conditions.
Despite the persuasiveness of some of the arguments
used to justify this strategy, standardization of certain
conditions remains an essential requisite for some factors,
such as gender and age. Furthermore, it is worth noting
that intermediate phenotypes are defined as factors of
vulnerability that are unraveled only in association with
select genetic or environmental conditions; thus, insufficient
standardization of conditions such as strain, husbandry, and
testing conditions may temper the ability of a given paradigm
to characterize and identify novel targets. This possibility
is particularly concerning in reference to the analysis of
virus-derived intermediate phenotypes. In fact, alterations
induced by viral perturbation of a neural pathway may not
result in full pathological processes, but may only confer
a liability to a disorder. As this condition may be revealed
only in presence of specific genetic or environmental factors,
experimental heterogenization may impoverish the heuristic
value of animal testing. These premises justify the need for
stringent standardization throughout all the experimental
phases of the study. In particular, extreme care should be
exercised in the standardization of the following aspects:
(i) inoculation protocol: this standardization is critical
to minimize apparent and predictable factors of
variability, such as the characteristics of the host
(strain, gender, age, etc.), the virus (strain, virulence,
tropism), and the infection procedure (infectious
dosage, regimen and route of administration). This
latter concept is particularly important, as experi-
mental infections are generally performed in utero or
during critical stages of early postnatal neurodevel-
opment, which are characterized by the occurrence of
numerous time-sensitive morphogenetic processes;
(ii) environmental conditions of husbandry and experi-
mental testing: this prescription is essential to control
(and preferably minimize) potential sources of stress.
Indeed, non-viral stress interferes with the patho-
physiological trajectory of virus-induced behavioral
sequelae and is a major confounder in behavioral
analysis. Stress-induced secretion of glucocorticoids
leads to inhibition of cell immunity and reactivation
of latent viruses [100–102]. Stress can also modulate
immune functions through other hormones (includ-
ing corticotrophin-releasing hormone, growth hor-
mone, and prolactin) and neurotransmitters, such
as catecholamines [103] and serotonin [104]. This
aspect can become extremely critical with models of
virus-induced sequelae that have been shown to alter
monoamine signaling, such as influenza virus and
BDV [59, 71, 74, 105, 106].
The reliability and translational impact of the findings
can also be enhanced with a thorough statistical approach,
which should not only be restricted to comparisons between
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cases and controls based on ANOVA or its nonparamet-
ric counterparts. Temporal analysis of behavior can be
fundamental to illustrate the progression of virus-induced
alterations. Alternatively, correlational approaches can be
employed to link particular behavioral outcomes to specific
variations in antibody panel, neurotransmitter levels, mor-
phology, electrophysiological alterations, drug sensitivity, or
other changes in molecular substrates.
Data analysis can also be improved by the elimination
of statistical artifacts, such as floor or ceiling effects, which
can be overcome by the incorporation of alternative methods
of analysis. Another typical example of artifact is offered
by the “litter effect”, defined as the tendency for littermates
to exhibit similar responses to the same early insult. This
potential pitfall can generate spurious statistical effects and
should always be avoided by limiting the number of tested
animals within each litter or by adjusting the statistical
analysis of the behavioral data to account for kinship within
the same treatment group.
Finally, a higher degree of replicability may be ensured
by the adoption of different criteria for the rejection of null
hypotheses. Indeed, the establishment of a P level of .05 as
a threshold for “statistical significance” has been extensively
criticized [107, 108] and is accepted only on account of
historical reasons [109]. However, the researcher should take
into account that the employment of extremely stringent
statistical conventions may lead to substantial drawbacks,
such as the reduction of the positive predictive value and the
heuristic validity of experimental procedures.
In conclusion, the design of any experiment aimed at
behavioral phenotyping of virus-induced neurobehavioral
sequelae should always take into account a number of key
issues:
(i) definition of meaningful endpoints, based on in-
termediate phenotypes revealed by cross-species
paradigms (testable in both humans and animals);
(ii) environmental standardization and elimination of
exogenous stressors;
(iii) analysis at different time points, to capture the
progression of viral pathogenesis;
(iv) correlational analysis between behavioral indices and
other paradigms, to strengthen the construct validity
of the animal model.
3. Concluding Remarks and Future Directions
Research on virus-induced neurobehavioral sequelae is
advancing as new methodological developments in trans-
lational strategies and behavioral sciences set a promising
scenario for future advancements. The field of phenotypic
characterization is at a critical juncture and has recently
witnessed the introduction of wide-range approaches, such
as those afforded by transcriptomics, proteomics, metabo-
nomics, and epigenetics. These techniques can provide a rich
source of candidate traits for the identification of interme-
diate phenotypes [110, 111]. Furthermore, these approaches
can identify patterns of a specific “viral signature”, which may
help facilitate the diagnosis and the link with a viral etiology
without requiring the analysis of viral material in numerous
clinical specimens [112–114].
The establishment of a neurophenomic approach to
psychiatric diagnosis and classification with extensive pro-
filing of affective and cognitive traits through batteries of
psychometric scales [115, 116] is bound to stimulate the
development of parallel guidelines and establish a sound
foundation for improvements in experimental design on
animal models, with a particular emphasis on construct
validity criteria. This perspective should strengthen our
understanding of the neural mechanisms underlying the
role of viruses in psychiatric disorders and accelerate the
identification of therapeutic targets.
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